APA引文

Elias, S., Kahlon, S., Kotzur, R., Kaynan, N., & Mandelboim, O. (2018). Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL). Oncoimmunology.

Citação norma Chicago

Elias, Shlomo, Shira Kahlon, Rebecca Kotzur, Noah Kaynan, and Ofer Mandelboim. "Obinutuzumab Activates FcγRI More Potently Than Other Anti-CD20 Antibodies in Chronic Lymphocytic Leukemia (CLL)." Oncoimmunology 2018.

MLA引文

Elias, Shlomo, et al. "Obinutuzumab Activates FcγRI More Potently Than Other Anti-CD20 Antibodies in Chronic Lymphocytic Leukemia (CLL)." Oncoimmunology 2018.